4.5 Letter

Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma

Journal

RESPIRATORY RESEARCH
Volume 18, Issue -, Pages -

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/s12931-017-0559-0

Keywords

Eosinophils; COPD; Asthma COPD overlap; ACOS

Funding

  1. Almirall
  2. AstraZeneca
  3. Boehringer Ingelheim
  4. Chiesi
  5. Genentech
  6. GlaxoSmithKline
  7. Glenmark
  8. Merck
  9. NAPP
  10. Novartis
  11. Pfizer
  12. Skyepharma
  13. Takeda
  14. Teva
  15. Therevance
  16. Verona

Ask authors/readers for more resources

Eosinophilic COPD appears to be a distinct patient subgroup with an increased corticosteroid response. Eosinophilic COPD has been labelled as part of the asthma COPD overlap syndrome (ACOS). We compared the clinical characteristics of eosinophilic COPD patients (without any clinical history of asthma) and COPD patients with a childhood history of asthma. COPD patients with asthma were characterised by more allergies and more exacerbations, but less eosinophilic inflammation. While terms such as ACOS are used to lump patients together, we report distinct differences between eosinophilic COPD and COPD patients with asthma, and propose that these groups should be split rather than lumped.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available